3Q sales, trends for key Bristol-Myers medicines

Associated Press

Global sales of key Bristol-Myers Squibb drugs in 2012's third quarter:

Drug name Use                   2012          Change from 2011

Plavix Blood thinner         $64 million   Down 96 percent

Avapro/Avalide High blood pressure   $95 million   Down 56 percent   

Reyataz HIV/AIDS              $363 million  Down 7 percent

Abilify Psychiatric disorders $676 million  Down 2 percent

Erbitux Various cancers       $173 million  Up 1 percent

Sustiva HIV/AIDS              $370 million  Up 3 percent

Baraclude Hepatitis B           $346 million  Up 11 percent

Sprycel Leukemia              $263 million  Up 25 percent

Orencia Rheumatoid arthritis  $307 million  Up 32 percent 

Onglyza Type 2 diabetes       $178 million  Up 40 percent

Yervoy Melanoma              $179 million  Up 48 percent

___

Source: Bristol-Myers Squibb Co.

View Comments (0)